Broad Spectrum Anti-Infective Therapy

PRIMALEUKIN, commonly known as interleukin-22 (IL-22), has a unique position as a combined antibacterial, anti-fungal and antiviral agent, harnessing and amplifying the body’s own natural defense against, and recovery from infection and as such has a potential to be targeted against several indications and commanding large market and multiple licensing opportunities. Granted patent has claims protection against all infections in most territories. There are well-validated production methods (human recombinant protein, E. coli or mammalian cell expression) and the regulatory bodies have helped with design of toxicology studies and clinical research. Anticipated toxicity is likely to be low; in animal models the compound has an excellent safety profile. Potent antibacterial activity of IL-22 has been demonstrated in animal models for the important human Gram negative bacteria like Escherichia coli and Klebsiella pneumonia. In addition to activities against Gram negative bacteria, antiviral (against HIV and HCV) and anti-fungal activity (against Candida) have been documented. Moreover, our unpublished data suggest a protective role in respiratory infections. Latest published data suggest that IL-22 is critical to restoration of thymic activity making it an ideal novel target to fight HIV infection and adding strength to using this compound as a broad spectrum protection.

Primaleukin™ is a recombinant human interleukin 22 (IL-22).
Interleukins are soluble proteins which interact with cell surface receptors. They play a key role in cellular signalling to control the immune system.

Primaleukin™ is involved in natural defenses and recovery from infection, initial clinical development target are Gram negative bacteria to be extended to other indications via partnership/collaborations. Patent granted for all infections in most territories

Broad Spectrum Activity (Various Published Studies)


These are all important human pathogens.


April 21-23, 2016 Dubai, United Arab Emirates
6th Global Experts Meeting & Expo on Nanomaterials and Nanotechnology 
Learn More

August 21-26, 2016 Melbourne, Australia
International Congress of Immunology
Learn More

August 22-25, 2016 in Sendai City, Miyagi, Japan
16th International Conference on Nanotechnology: Green Nanotechnology for a Sustainable Society
Learn More

October 3-5, 2016, London, United Kingdom
4th International Conference on Geriatrics & Gerontology
Learn More

October 9-10, 2016 Dubai, United Arab Emirates
International Congress in Aesthetics, Anti-Ageing and Medical
Learn More

October 12-13, 2016, San Francisco, California, USA
8th Annual Personalized &Precision Medicine Conference
Learn More

December, 8-10, 2016, Dubai, United Arab Emirates
7th International Conference on Clinical Nutrition
Learn More

February 15-17, 2017, Tokyo, Japan
International Nanotechnology Exhibition Conference
Learn More

February 16-17, 2017, London, United Kingdom
19th International Conference on Immunology
Learn More

June 21-22, 2017, Vienna, Austria
19th International Conference on Nanotechnology and Nanomedicine
Learn More

July 23-27, 2017, San Francisco, California, USA
International Association of Gerontology and Geriatrics Conference
Learn More

October 22-27, 2017 Buenos Aires, Argentina
21st IUNS-ICN International Congress of Nutrition
Learn More